STA
KRYS icon

Summit Trail Advisors’s Krystal Biotech KRYS Stock Holding History

Summit Trail Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,464
Closed -$1.14M – 1344
2025
Q3 		$1.14M Sell
6,464
-36
-0.6% -$5.39K 0.02% 754
2025
Q2 		$893K Buy
+6,500
New +$955K 0.02% 520
2024
Q4 		– Sell
-10,401
Closed -$1.89M – 597
2024
Q3 		$1.89M Buy
+10,401
New +$2.01M 0.05% 166
2023
Q4 		– Sell
-4,555
Closed -$528K – 579
2023
Q3 		$528K Hold
4,555
– – 0.02% 258
2023
Q2 		$535K Buy
+4,555
New +$465K 0.02% 253

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Summit Trail Advisors's KRYS Position: Q4 2025 in Review

Summit Trail Advisors sold out of Krystal Biotech (KRYS) in Q4 2025, closing a stake of 6,464 shares — an estimated $1.14M sold.

Summit Trail Advisors first reported a position in KRYS in Q2 2023 and held it in 5 quarters. The position peaked at $1.89M in Q3 2024. 334 funds tracked by Wall St. Rank hold KRYS as of Q4 2025.

  • Summit Trail Advisors reported no remaining Krystal Biotech position as of Q4 2025 after selling out during the quarter.
  • Summit Trail Advisors sold 6,464 Krystal Biotech shares in Q4 2025, an estimated $1.14M.
  • Summit Trail Advisors first reported a position in Krystal Biotech in Q2 2023 and held it in 5 quarters.
  • Summit Trail Advisors's Krystal Biotech position peaked at $1.89M in Q3 2024.
  • 334 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2025.

Based on Summit Trail Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.